Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = Array, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39
Jun 042012
 

The Hygiology Post is presenting information about a company that seems to have much potential to help many people. 2012 may be a pivotal year in determining how helpful the patented technologies may actually be for people.    

Senesco Technologies has continued to update information on its web site (https://www.senesco.com/; obtained on 06-04-12). As a matter of disclosure : The author continues to be a current shareholder in the company.

The Senesco Technologies web site ( https://www.senesco.com/newsitem.php?id=253; obtained on 6-04-12) today posted what does appear to be exceptionally important information that could portend of future results. Here is an excerpt:

“6/4/2012

Senesco Provides SNS01-T Update on Phase 1b/2a Multiple Myeloma Trial

BRIDGEWATER, N.J. (June 4th, 2012) – Senesco Technologies, Inc. (‘Senesco’ or the ‘Company’) (NYSE MKT: SNT) reported today on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster presented today at the 2012 Annual Meeting of the American Society of Clinical Oncology.

To date five patients have been enrolled into the study. So far one patient has completed the 6 week dosing schedule. This patient’s disease was considered stable, no disease progression, based on key disease markers including monoclonal protein when evaluated at the end of weeks 3 and 6. Two patients were withdrawn from the study due to disease progression, and two patients are currently being treated. No disease limiting toxicities have been recorded to date.

‘We are encouraged that there is an indication that SNS01-T is performing as designed even at this low dose,’ stated Harlan Waksal, M.D., Chairman of Senesco. ‘At this dose level we had expected to evaluate only safety. So seeing an indication of activity, even in a single patient, is a bonus.’

In the study, patients are dosed twice-weekly for 6 weeks followed by an observation period. The first group of patients receives 0.0125 mg/kg by intravenous infusion. At the end of 6 weeks of dosing, safety data for the group will be reviewed before the subsequent group receives a higher dosage. The escalated doses administered to the second to fourth groups will be 0.05, 0.2 and 0.375 mg/kg, respectively.”

The Hygiology Post welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.

 

Louis DeCola, Jr.                                    © 2012 The Hygiology Post